SEARCH

SEARCH BY CITATION

Keywords:

  • Febrile seizures;
  • GEFS+;
  • SCN1A;
  • SCN1B;
  • GABRG2;
  • Age of onset

Summary

  1. Top of page
  2. Summary
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

SCN1A is the most clinically relevant epilepsy gene and is associated with generalized epilepsy and febrile seizure plus (GEFS+) and Dravet syndrome. We postulated that earlier onset of febrile seizures in the febrile seizure (FS) and febrile seizure plus (FS+) phenotypes may occur in the presence of a SCN1A mutation. This was because of the age-related onset of Dravet syndrome, which typically begins in the first year of life. We found that patients with FS and FS+ with SCN1A mutations had earlier median onset of febrile seizures compared to the population median. Patients with GABRG2 mutations had a similar early onset in contrast to patients with SCN1B mutations where onset was later. This study is the first to demonstrate that a specific genetic abnormality directly influences the FS and FS+ phenotype in terms of age of onset.

Febrile seizures are the most common form of seizures and occur in 2–5% of children. These seizures begin between the age of 3 months and 6 years, with a median age of onset of 18 months (Offringa et al., 1991). Febrile seizures have a genetic basis and usually follow complex inheritance, where multiple genes and environmental factors play a role.

Children with febrile seizures may be part of a family with the familial epilepsy syndrome of generalized epilepsy and febrile seizure plus (GEFS+) (Scheffer & Berkovic, 1997). Febrile seizure (FS) and febrile seizure plus (FS+) are the two most common phenotypes in GEFS+. Three genes have been confirmed to be associated with the GEFS+ syndrome but have been identified in only 10–20% families studied: two sodium channel subunit genes encoding the alpha 1 and beta 1 subunit (SCN1A, SCN1B) and the gamma 2 γ-aminobutyric acid (GABA)A receptor subunit gene, GABRG2 (Wallace et al., 1998, 2001a,b, 2002). The most commonly reported GEFS+ gene is SCN1A, in which missense mutations are found.

Dravet syndrome is associated with SCN1A mutations in about 70–80% cases, and represents the severe end of the GEFS+ spectrum. SCN1A mutations in Dravet syndrome include missense, truncation, or copy number variation. Marini et al. (2007) found that patients with Dravet syndrome and a SCN1A mutation had an earlier onset of seizures with fever compared to those who were mutation negative.

We, therefore, hypothesized that patients with FS and FS+ in GEFS+ families with SCN1A mutations who first presented with a febrile seizure, had an earlier age of onset compared to the age of onset of febrile seizures in the general population. We also examined the age of onset of febrile seizures in patients with SCN1B or GABRG2 mutations. Whether the nature of the GEFS+ gene alters the age of onset of febrile seizures has not been determined.

Patients and Methods

  1. Top of page
  2. Summary
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Families

Twelve multigenerational families were identified with the GEFS+ syndrome and a known mutation of major effect. There were four families with SCN1A mutations (Scheffer & Berkovic, 1997; Wallace et al., 2001b); (1 unpublished family), six families with SCN1B mutations (Wallace et al., 1998, 2002; Singh et al., 1999; Scheffer et al., 2007), and two families with GABRG2 mutations (Wallace et al., 2001a, Harkin et al., 2002;Marini et al., 2003). Patients with a pure phenotype of FS or FS+ who presented initially with a febrile seizure were included. If febrile seizures occurred after afebrile seizures, the subjects were not included in this cohort.

Epilepsy phenotypes

The phenotypes of affected family members were classified according to the international classification of epilepsy syndromes (Commission, 1989) and the description of GEFS+ phenotypes (Scheffer & Berkovic, 1997; Singh et al., 1999). In FS, seizures occurred between 3 months and 6 years of age. If seizures persisted beyond the age of 6 years and/or were accompanied by afebrile convulsions then the diagnosis was FS+. Patients with extended phenotypes were excluded, including patients with partial seizures (Scheffer et al., 2007).

Literature review

A literature search was performed to review febrile seizure onset in other families with known genetic mutations (Abou-Khalil et al., 2001; Escayg et al., 2001; Kananura, et al., 2002; Audenaert et al., 2003; Spampanato et al., 2004; Nagao et al., 2005, Pineda-Trujillo et al., 2005; Audenaert et al., 2006; Barela et al., 2006; Colosimo et al., 2007). Because some syndromes were phenotyped according to different definitions, these were modified to be consistent with the definitions used here. For example, some cases were called FS; however, seizure offset occurred after 6 years so we reclassified these cases as FS+ (Barela et al., 2006). In other cases, febrile seizures and afebrile generalized seizures were noted and we reclassified these as FS+ (Abou-Khalil et al., 2001; Barela et al., 2006). If partial seizures were documented, these patients were not included in our analysis.

Statistical analysis

Mann-Whitney U test was used to determine the difference in the median age of onset between different genes. Statistical analysis was performed using the statistical program, SPSS version 11.5 (SPSS, Chicago, IL, U.S.A.).

Results

  1. Top of page
  2. Summary
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Epilepsy Research Centre data

A total of 105 patients in 12 families for whom we had detailed clinical information were identified with SCN1A, SCN1B, or GABRG2 mutations. Sixty-two patients presented with a febrile seizure where the age of onset was known and had a FS or FS+ phenotype. An additional 43 patients were excluded for the following reasons: they had a more complex phenotype than FS and FS+ (31), their initial seizure was an afebrile seizure or it was unclear whether a fever was present (6), or their age of onset was imprecise (6).

The median age of onset of FS and FS+ was 12 months in subjects with SCN1A and GABRG2 mutations (Table 1, Fig. 1). The median age of onset for children with an SCN1A mutation was significantly lower than for children with an SCN1B mutation (p = 0.001, Mann–Whitney U test). There was no significant difference in onset between individuals with SCN1A and GABRG2 mutations.

Table 1.   Comparison of age of onset of FS and FS+ in SCN1A, SCN1B, and GABRG2 families
StudiesGene mutationNumber ofAge of onset (months)References
FamiliesFS subjectsFS+ subjectsTotal subjectsMedian Value Range (min–max)p-value (compared to SCN1A)
  1. FS, febrile seizure; FS+, febrile seizure plus; GEFS+, generalized epilepsy and febrile seizure plus; SCN1A, sodium channel alpha1 subunit gene; SCN1B, sodium channel beta1 subunit gene; GABRG, gamma 2 GABAA receptor subunit gene; min, minimum; max, maximum; p-value derived using Mann-Whitney U test.

  2. aStatistically significant.

Our seriesSCN1A49112012.06–108  
SCN1B615132824.04–420.001a
GABRG221131411.56–240.986
Other reported familiesSCN1A712112311.05–38 (Abou-Khalil et al., 2001; Escayg et al., 2001; Spampanato et al., 2004; Nagao et al., 2005; Pineda-Trujillo et al., 2005; Barela et al., 2006; Colosimo et al., 2007)
SCN1B131430.012–360.033a(Audenaert et al., 2003)
GABRG2230318.013–360.158(Audenaert et al., 2006; Kananura, et al. 2002)
CombinedSCN1A1121224312.05–108  
SCN1B718143224.04–42<0.001a
GABRG241431713.06–360.559

Figure 1.   Box plot showing the median age of onset of febrile seizure (FS) in individuals in our families compared with families in the literature. There is a significantly earlier age of onset in patients with SCN1A mutations compared to individuals with SCN1B mutations in both groups. Dark lines denote median, boxes denote interquartile ranges (25–75th percentiles), and error bars show 95% confidence intervals.

Download figure to PowerPoint

image

Analysis of families from the literature

We performed a similar analysis on the families in the literature who had SCN1A, SCN1B, or GABRG2 mutations. Of the 12 families with mutations, only 10 were included in our analysis, as there were insufficient clinical data on two families (Sugawara et al., 2001; Lossin et al., 2003). The median age of onset for mutations in each gene based on the clinical data of the reported families is shown in Table 1. Similar findings emerged to our dataset, with the median age of onset of patients with SCN1A mutations being 11 months, and a significantly earlier median onset in children with SCN1A mutations compared with SCN1B mutations.

Discussion

  1. Top of page
  2. Summary
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

The critical observation was that in two independent cohorts of individuals with FS or FS+ and SCN1A mutations, the median age of onset was 11–12 months compared with the population median of 18 months (Offringa et al., 1991). This is the first demonstration that the specific gene associated with benign phenotypes such as FS or FS+ may affect age of onset of febrile seizures. This is not surprising given the frequent onset of SCN1A-related epileptic encephalopathies beginning in individuals younger than 1 year of age (Harkin, et al. 2007; Marini et al., 2007). This is likely to reflect age-related developmental expression of the SCN1A protein, rendering the individual susceptible to seizures from about 6 months. This is supported by the developmental expression pattern of SCN1A recently demonstrated in mouse brain (Ogiwara et al., 2007).

It is enticing that our data also suggest an earlier median onset in individuals with GABRG2 mutations, but not SCN1B mutations, suggesting that this is not specific to sodium channel abnormalities. However, the numbers of patients in the SCN1B and GABRG2 groups were small.

The cause of the earlier age of onset of febrile seizures in patients with SCN1A mutations remains unclear. Although the genetic heterogeneity of febrile seizures is well accepted, this is the first demonstration that a specific genetic abnormality directly influences the phenotype in terms of age of onset. This is likely to reflect the maturation dependent biologic vulnerability of the sodium channel that is critical to neuronal excitability. Functional studies examining the age of developmental expression of different ion channel subunits may help to elucidate this hypothesis.

Acknowledgments

  1. Top of page
  2. Summary
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

We thank the families who have participated in our research. Dr Sijben was supported by Nationaal Epilepsie Fonds of The Netherlands. Dr Sithinamsuwan was supported by funding from Phramongkutklao Hospital, Royal Thai Army. Support was also obtained from the National Health and Medical Research Council of Australia.

We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure: None of the authors has any conflict of interest to disclose.

References

  1. Top of page
  2. Summary
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References
  • Commission on Classification and Terminology of the International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389399.
  • Abou-Khalil B, Ge Q, Desai R, Ryther R, Bazyk A, Bailey R, Haines JL, Sutcliffe JS, George AL Jr. (2001) Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology 57:22652272.
  • Audenaert D, Claes L, Ceulemans B, Lofgren A, Van Broeckhoven C, De Jonghe P. (2003) A deletion in SCN1B is associated with febrile seizures and early-onset absence epilepsy. Neurology 61:854856.
  • Audenaert D, Schwartz E, Claeys KG, Claes L, Deprez L, Suls A, Van Dyck T, Lagae L, Van Broeckhoven C, Macdonald RL, De Jonghe P. (2006) A novel GABRG2 mutation associated with febrile seizures. Neurology 67:687690.
  • Barela AJ, Waddy SP, Lickfett JG, Hunter J, Anido A, Helmers SL, Goldin AL, Escayg A. (2006) An epilepsy mutation in the sodium channel SCN1A that decreases channel excitability. J Neurosci 26:27142723.
  • Colosimo E, Gambardella A, Mantegazza M, Labate A, Rusconi R, Schiavon E, Annesi F, Cassulini RR, Carrideo S, Chifari R, Canevini MP, Canger R, Franceschetti S, Annesi G, Wanke E, Quattrone A. (2007) Electroclinical features of a family with simple febrile seizures and temporal lobe epilepsy associated with SCN1A loss-of-function mutation. Epilepsia 48:16911696.
  • Escayg A, Heils A, MacDonald BT, Haug K, Sander T, Meisler MH. (2001) A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus--and prevalence of variants in patients with epilepsy. Am J Hum Genet 68:866873.
  • Harkin LA, Bowser DN, Dibbens LM, Singh R, Phillips F, Wallace RH, Richards MC, Williams DA, Mulley JC, Berkovic SF, Scheffer IE, Petrou S. (2002) Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 70:530536.
  • Harkin LA, McMahon JM, Iona X, Dibbens L, Pelekanos JT, Zuberi SM, Sadleir LG, Andermann E, Gill D, Farrell K, Connolly M, Stanley T, Harbord M, Andermann F, Wang J, Batish SD, Jones JG, Seltzer WK, Gardner A; Infantile Epileptic Encephalopathy Referral Consortium, Sutherland G, Berkovic SF, Mulley JC, Scheffer IE. (2007) The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130(Pt 3):843852.
  • Kananura C, Haug K, Sander T, Runge U, Gu W, Hallmann K, Rebstock J, Heils A, Steinlein OK. (2002) A splice-site mutation in GABRG2 associated with childhood absence epilepsy and febrile convulsions. Arch Neurol 59:11371141.
  • Lossin C, Rhodes TH, Desai RR, Vanoye CG, Wang D, Carniciu S, Devinsky O, George AL Jr. (2003) Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 23:1128911295.
  • Marini C, Harkin LA, Wallace RH, Mulley JC, Scheffer IE, Berkovic SF. (2003) Childhood absence epilepsy and febrile seizures: a family with a GABA(A) receptor mutation. Brain 126:230240.
  • Marini C, Mei D, Temudo T, Ferrari AR, Buti D, Dravet C, Dias AI, Moreira A, Calado E, Seri S, Neville B, Narbona J, Reid E, Michelucci R, Sicca F, Cross HJ, Guerrini R. (2007) Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia 48:16781685.
  • Nagao Y, Mazaki-Miyazaki E, Okamura N, Takagi M, Igarashi T, Yamakawa K. (2005) A family of generalized epilepsy with febrile seizures plus type 2-a new missense mutation of SCN1A found in the pedigree of several patients with complex febrile seizures. Epilepsy Res 63:151156.
  • Offringa M, Hazebroek-Kampschreur AA, Derksen-Lubsen G. (1991) Prevalence of febrile seizures in Dutch schoolchildren. Paediatr Perinat Epidemiol 5:181188.
  • Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, Takeuchi T, Itohara S, Yanagawa Y, Obata K, Furuichi T, Hensch TK, Yamakawa K. (2007) Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 27:59035914.
  • Pineda-Trujillo N, Carrizosa J, Cornejo W, Arias W, Franco C, Cabrera D, Bedoya G, Ruiz-Linares A. (2005) A novel SCN1A mutation associated with severe GEFS+ in a large South American pedigree. Seizure 14:123128.
  • Scheffer IE, Berkovic SF. (1997) Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 120(Pt 3):479490.
  • Scheffer IE, Harkin LA, Grinton BE, Dibbens LM, Turner SJ, Zielinski MA, Xu R, Jackson G, Adams J, Connellan M, Petrou S, Wellard RM, Briellmann RS, Wallace RH, Mulley JC, Berkovic SF. (2007) Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain 130:100109.
  • Singh R, Scheffer IE, Crossland K, Berkovic SF. (1999) Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol 45:7581.
  • Spampanato J, Kearney JA, De Haan G, McEwen DP, Escayg A, Aradi I, MacDonald BT, Levin SI, Soltesz I, Benna P, Montalenti E, Isom LL, Goldin AL, Meisler MH. (2004) A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction. J Neurosci 24:1002210034.
  • Sugawara T, Mazaki-Miyazaki E, Ito M, Nagafuji H, Fukuma G, Mitsudome A, Wada K, Kaneko S, Hirose S, Yamakawa K. (2001) Nav1.1 mutations cause febrile seizures associated with afebrile partial seizures. Neurology 57:703705.
  • Wallace RH, Wang DW, Singh R, Scheffer IE, George AL Jr, Phillips HA, Saar K, Reis A, Johnson EW, Sutherland GR, Berkovic SF, Mulley JC. (1998) Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet 19:366370.
  • Wallace RH, Marini C, Petrou S, Harkin LA, Bowser DN, Panchal RG, Williams DA, Sutherland GR, Mulley JC, Scheffer IE, Berkovic SF. (2001a) Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 28:4952.
  • Wallace RH, Scheffer IE, Barnett S, Richards M, Dibbens L, Desai RR, Lerman-Sagie T, Lev D, Mazarib A, Brand N, Ben-Zeev B, Goikhman I, Singh R, Kremmidiotis G, Gardner A, Sutherland GR, George AL Jr, Mulley JC, Berkovic SF. (2001b) Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet 68:859865.
  • Wallace RH, Scheffer IE, Parasivam G, Barnett S, Wallace GB, Sutherland GR, Berkovic SF, Mulley JC. (2002) Generalized epilepsy with febrile seizures plus: mutation of the sodium channel subunit SCN1B. Neurology 58:14261429.